Antileishmanial efficacy of amphotericin B bearing emulsomes against experimental visceral leishmaniasis

References

• Agrawal AK, Agrawal A, Pal A, Guru PY, Gupta CM. Superior chemotherapeutic efficacy of amphotericin B in tuftsin-bearing liposomes against Leishmania donovani infection in hamsters. J Drug Target 2002; 10: 41–45
   PubMed Web of Science ®Google Scholar
• Ahmad I, Sarkar AK, Bachhawat BK. Design of liposomes to improve delivery of amphotericin B in the treatment of aspergillosis. J Mol Cell Biochem 1989; 91: 85–90
   PubMed Web of Science ®Google Scholar
• Alving CR, Weldon JS, Munnell JF, Hanson WL. Liposomes in leishmaniasis: The lysosome connection. Receptor mediated targeting of drugs, G Gregoriadis, G Poste, J Senior, A Trouet. Plenum Press, New York and London 1984; Vol. 82: 317–331
   Google Scholar
• Amselem S, Friedman D. 1997. US Patent 5,662, 932 Solid fat nanoemulsions.
   Google Scholar
• Amselem S, Yogev A, Zawoznik E, Friedman D. Emulsomes, a novel drug delivery technology. Proc Int Symp Control Release Bioact Mater 1994; 21: 1368–1369
   Google Scholar
• Banerjee G, Nandi G, Mahato SB, Pakrashi A, Basu MK. Drug delivery system: Targeting of pentamidines to specific sites using sugar-grafted liposomes. J Antimicrob Chemother 1996; 38: 145–150
   PubMed Web of Science ®Google Scholar
• Banerjee G, Medda S, Basu MK. A novel peptide-grafted liposomal delivery system targeted to macrophages. Antimicrob Agents Chemother 1998; 42: 348–351
   PubMed Web of Science ®Google Scholar
• Berman JD, Hanson WL, Chapman WL, Alving CR, Lopez-Berestein G. Antileishmanial activity of liposome-encapsulated amphotericin B in hamsters and monkeys. Antimicrob Agents Chemother 1986; 30: 847–851
   PubMed Web of Science ®Google Scholar
• Bora D. Epidemiology of visceral leishmaniasis in India. Natl Med J India 1999; 12: 62–68
   PubMed Web of Science ®Google Scholar
• Das PK, Murray GJ, Zairzow GC, Brady RO, Barranger JA. Lectin specific targeting of β-glucocerebrosidase to different liver cells via glycosylated liposomes. Biochem Med 1985; 33: 124–131
   PubMed Web of Science ®Google Scholar
• Das N, Mahato SB, Naskar K, Ghosh DK, Basu MK. Targeting of urea stibamine encapsulated in liposomes to reticuloendothelial system for the treatment of experimental leishmaniasis. Biochem Med Metab Biol 1990; 43: 133–139
   PubMedGoogle Scholar
• Dea-Ayuela MA, Rama-Iniguez S, Sanchez-Brunete JA, Torrado JJ, Alunda JM, Bolas-Fernandez F. Anti-leishmanial activity of a new formulation of amphotericin B. Trop Med Int Health 2004; 9: 981–990
   PubMed Web of Science ®Google Scholar
• Dube A, Sharma P, Srivastava JK, Misra A, Naik S, Katiyar JC. Vaccination of langur monkeys (Presbytis entellus) against Leishmania donovani with autoclaved L. major plus BCG. Parasitology 1998; 116: 219–221
   PubMed Web of Science ®Google Scholar
• Dube A, Srivastava JK, Sharma P, Chaturvedi A, Katiyar JC, Naik S. Leishmania donovani: Cellular and humoral immune responses in Indian langur monkeys, Presbytis entellus. Acta Tropica 1999; 73: 37–48
   PubMed Web of Science ®Google Scholar
• Dube A, Singh N, Sundar S, Singh N. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol Res 2005; 96: 216–223
   PubMed Web of Science ®Google Scholar
• Echevarria I, Barturen C, Renedo MJ, Troconiz IF, Dios-Vieitez MC. Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin B-deoxycholate in rats. Antimicrob Agents Chemother 2000; 44: 898–904
   PubMed Web of Science ®Google Scholar
• Espuelas MS, Legrand P, Loiseau PM, Bories C, Barratt G, Irache JM. In vitro antileishmanial activity of amphotericin B loaded in poly (epsilon-caprolactone) nanospheres. J Drug Target 2002; 10: 593–599
   PubMed Web of Science ®Google Scholar
• Fry DW, White JC, Goldman ID. Rapid separation of low molecular weight solutes from liposomes without dilution. Anal Biochem 1978; 90: 809–815
   PubMed Web of Science ®Google Scholar
• Ghosh P, Bacchawat BK. Grafting of different glycosides on the surface of liposomes and its effects on the tissue distribution of 125I labelled γ-globulin encapsulated in liposomes. Biochim Biophys Acta 1980; 632: 560–565
   Google Scholar
• Goldsmith DR, Perry CM. Amphotericin B lipid complex: In visceral leishmaniasis. Drugs 2004; 64: 1905–1911
   PubMed Web of Science ®Google Scholar
• Gupta S, Vyas SP. Development and characterization of amphotericin B bearing emulsomes for passive and active macrophage targeting. J Drug Target 2007; 15: 206–217
   PubMed Web of Science ®Google Scholar
• Guru PY, Agarwal AK, Singha UK, Singhal A, Gupta CM. Drug targeting in Leishmania donovani infections using tuftsin bearing liposomes as drug vehicles. FEBS Lett 1989; 245: 204–208
   PubMed Web of Science ®Google Scholar
• Hartsel S, Boland J. Amphotericin B: New life for an old drug. Trends Pharmacol Sci 1996; 17: 445–449
   PubMed Web of Science ®Google Scholar
• Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: Recent progress and future directions. Clin Infect Dis 1996; 22(Suppl 2)S133–S144
   PubMed Web of Science ®Google Scholar
• Kafetzis DA, Velissariou IM, Stabouli S, Mavrikou M, Delis D, Liapi G. Treatment of paediatric visceral leishmaniasis: Amphotericin B or pentavalent antimony compounds?. Int J Antimicrob Agents 2005; 25: 26–30
   PubMed Web of Science ®Google Scholar
• Khan MA, Nasti TH, Owais M. Incorporation of amphotericin B in tuftsin-bearing liposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice. J Antimicrob Chemother 2005; 56: 726–731
   PubMed Web of Science ®Google Scholar
• Kole L, Sarkar K, Mahato SB, Das PK. Neoglycoprotein conjugated liposomes as macrophage specific drug carrier in the therapy of leishmaniasis. Biochem Biophy Res Commun 1994; 200: 351–358
   PubMed Web of Science ®Google Scholar
• Kretschmar M, Amselem S, Zawoznik E, Mosbach K, Dietz A, Hof H, Nichterlein T. Efficient treatment of murine systemic infection with Candida albicans using amphotericin B incorporated in nanosize range particles (emulsomes). Mycoses 2001; 44: 281–286
   PubMed Web of Science ®Google Scholar
• Lowell GH, Kaminski RW, VanCott TC, Slike B, Kersey K, Zawoznik E, Loomis-Price L, Smith G, Redfield RR, Amselem S, Birx DL. Proteosomes, emulsomes, and cholera toxin B improve nasal immunogenicity of human immunodeficiency virus gp160 in mice: Induction of serum, intestinal, vaginal, and lung IgA and IgG. J Infect Dis 1997; 175: 292–301
   PubMed Web of Science ®Google Scholar
• Melby PC. Recent developments in leishmaniasis. Curr Opin Infect Dis 2002; 15: 485–490
   PubMed Web of Science ®Google Scholar
• Mitra M, Mandal AK, Chatterjee TK, Das N. Targeting of mannosylated liposome incorporated benzyl derivative of Penicillium nigricans derived compound MT81 to reticuloendothelial systems for the treatment of visceral leishmaniasis. J Drug Target 2005; 13: 285–293
   PubMed Web of Science ®Google Scholar
• Mullen AB, Baillie AJ, Carter KC. Visceral leishmaniasis in the BALB/c mouse: A comparison of the efficacy of a nonionic surfactant formulation of sodium stibogluconate with those of three proprietary formulations of amphotericin B. Antimicrob Agents Chemother 1998; 42: 2722–2725
   PubMed Web of Science ®Google Scholar
• New RRC. Introduction and preparation of liposomes. Liposomes: A practical approach, RRC New. IRL Press, Oxford 1990; 1–104
   Google Scholar
• Pal R, Dube A, Rizvi SY, Kundu B, Mathur KB, Katiyar JC. Leishmania donovani in hamsters: Stimulation of non-specific resistance by some novel glycopeptide and impact on therapeutic efficacy. Experientia 1991; 47: 486–490
   PubMedGoogle Scholar
• Rex JH, Walsh TJ. Estimating the true cost of amphotericin B. Clin Infect Dis 1999; 29: 1408–1410
   PubMed Web of Science ®Google Scholar
• Rocheleau H, Saint-Germain G, Barwicz J, Gruda I, Therien HM. Modulation of amphotericin B activity by association with mannose ester. Immunopharmacol Immunotoxicol 1994; 16: 419–436
   PubMed Web of Science ®Google Scholar
• Sanchez-Brunete JA, Dea MA, Rama S, Bolas F, Alunda JM, Raposo R, Mendez MT, Torrado-Santiago S, Torrado JJ. Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres. Antimicrob Agents Chemother 2004; 48: 3246–3252
   PubMed Web of Science ®Google Scholar
• Saxena S, Ghosh PC. Biodistribution of amphotericin B when delivered through cholesterol hemisuccinate vesicles in normal and A. fumigatus infected mice. Pharm Res 2000; 17: 1236–1242
   PubMed Web of Science ®Google Scholar
• Sunamoto J, Gato M, Iida T, Hara K, Saito A, Tomonega A. Polymer coated liposomes for drug delivery to target specific organs. Receptor mediated targeting of drugs, G Gregoriadis, J Senior, A Trouet. Plenum Press, New York 1985; 359–371
   Google Scholar
• Sundar S, Rai M. Advances in the treatment of leishmaniasis. Curr Opin Infect Dis 2002; 15: 593–598
   PubMed Web of Science ®Google Scholar
• Szoka FC, Mayhew E, Jr. Alteration of liposome disposition in vivo by bilayer situated carbohydrates. Biochim Biophys Res Commun 1983; 110: 140–147
   PubMed Web of Science ®Google Scholar
• Townsed RW, Zutshi A, Bekersky I. Biodistribution of 4-[(14)C] cholesterol-AmBisome following a single intravenous administration to rats. Drug Metab Dispos 2001; 29: 681–685
   PubMed Web of Science ®Google Scholar
• Venier-Julienne MC, Vouldoukis I, Monjour L, Benoit JP. In vitro study of the anti-leishmanial activity of biodegradable nanoparticles. J Drug Target 1995; 3: 23–29
   PubMed Web of Science ®Google Scholar
• Venkatesan N, Vyas SP. Polysaccharide coated liposomes for oral immunization: Development and characterization. Int J Pharm 2000; 203: 169–177
   PubMed Web of Science ®Google Scholar
• Vyas SP, Katare YK, Mishra V, Sihorkar V. Ligand directed macrophage targeting of amphotericin B loaded liposomes. Int J Pharm 2000; 210: 1–14
   PubMed Web of Science ®Google Scholar
• Vyas SP, Quraishi S, Gupta S, Jaganathan KS. Aerosolized liposome-based delivery of amphotericin B to alveolar macrophages. Int J Pharm 2005; 296: 12–25
   PubMed Web of Science ®Google Scholar
• Vyas SP, Subhedar R, Jain S. Development and characterization of emulsomes for sustained and targeted delivery of an antiviral agent to liver. J Pharm Pharmacol 2006; 58: 321–326
   PubMed Web of Science ®Google Scholar
• Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: Clinical efficacy and toxicities. Clin Infect Dis 1998; 27: 603–618
   PubMed Web of Science ®Google Scholar
• Yachi K, Kikuchi H, Yamauchi H, Hirota S, Tomikawa M. Distribution of liposomes containing mannobiose esters of fatty acid in rats. J Microencapsul 1995; 12: 377–388
   PubMed Web of Science ®Google Scholar